Physician profile
Satheesh Chonat
NPI 1639300544
$146,830.65
in general payments reported to CMS, 2019-2025
13 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,141 · 2020: $6,424 · 2021: $8,600 · 2022: $16K · 2023: $29K · 2024: $28K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $65K · Travel and Lodging: $34K · Honoraria: $9,660 · Food and Beverage: $2,368 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,349.00 |
| Travel and Lodging | $33,564.59 |
| Honoraria | $9,660.00 |
| Food and Beverage | $2,367.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $950.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $66,033.77 | 2019-2025 | Ultomiris |
| Octapharma USA, INC. | $19,193.36 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17,340.50 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $13,980.20 | 2020-2024 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $9,928.50 | 2021-2025 | |
| F. Hoffmann-La Roche Ag | $8,107.42 | 2023-2025 | |
| Novo Nordisk INC | $5,015.00 | 2022 | |
| Samsung Bioepis Co., Ltd. | $3,070.00 | 2024 | |
| Amgen INC. | $2,075.07 | 2023-2025 | Bkemv |
| Daiichi Sankyo INC. | $1,800.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $286.83 | 2022-2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satheesh Chonat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.